MDGLMadrigal Pharmaceuticals Inc
MDGL
Madrigal Pharmaceuticals Inc6,960
Mkt Cap
$12.11BVolume
114,529.0052W High
$615.0052W Low
$265.00PE Ratio
-41.02MDGL Fundamentals
Price
$527.79Prev Close
$527.69Open
$529.7150D MA
$475.58Beta
0.81Avg. Volume
367,332.68EPS (Annual)
-$12.85P/B
20.00Rev/Employee
$1.05M$12,423.38
Madrigal Pharmaceuticals (NASDAQ:MDGL) Share Price Crosses Above 200 Day Moving Average - Time to Sell?
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell...
MarketBeat·7d ago
Rheos Capital Works Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Rheos Capital Works Inc. reduced its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent filing with...
MarketBeat·15d ago
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Capricorn Fund Managers Ltd bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent filing...
MarketBeat·16d ago
Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
Toth Financial Advisory Corp bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the...
MarketBeat·18d ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendatio...
MarketBeat·21d ago
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...
PR Newswire·22d ago
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Hennion & Walsh Asset Management Inc. cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 36.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,163 shares of the biopha...
MarketBeat·22d ago
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent...
MarketBeat·23d ago
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·26d ago
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·26d ago
<
1
2
...
>